QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foringer, J. R Articles by Guntupalli, J. S Search for Related Content PubMed PubMed Citation Articles by Foringer, J. R Articles by Guntupalli, J. S

Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer

¹ Assistant Professor, Division of Renal Diseases and Hypertension, Medical School, The University of Texas-Houston; Section of Nephrology, MD Anderson Cancer Center, The University of Texas, Houston, TX
² Professor, Department of Pathology and Laboratory Medicine, Medical School, The University of Texas-Houston
³ Clinical Fellow, Division of Renal Diseases and Hypertension, Medical School, The University of Texas-Houston
⁴ Associate Professor, Division of Renal Diseases and Hypertension, Medical School, The University of Texas-Houston; Section of Nephrology, MD Anderson Cancer Center, The University of Texas
⁵ Assistant Professor, Division of Renal Diseases and Hypertension, Medical School, The University of Texas-Houston; Section of Nephrology, MD Anderson Cancer Center, The University of Texas
⁶ Associate Professor, Division of Renal Diseases and Hypertension, Medical School, The University of Texas-Houston; Section of Nephrology, MD Anderson Cancer Center, The University of Texas

Reprints: Dr. Foringer, Division of Renal Diseases and Hypertension, Medical School, The University of Texas-Houston, 6431 Fannin St., MSB 4.148, Houston, TX 77030-1501, fax 713/500-6882, john.r.foringer{at}uth.tmc.edu

OBJECTIVE: To report a case of acute renal failure associated with the administration of imatinib mesylate.

CASE SUMMARY: A 64-year-old man diagnosed with prostate cancer was enrolled in a Phase I trial of imatinib mesylate plus taxotere on a protocol that required a run-in period of imatinib mesylate alone. During therapy with imatinib mesylate, the patient developed acute renal failure, requiring hemodialysis. A renal biopsy revealed tubular vacuolization. Renal failure resolved with cessation of imatinib mesylate.

DISCUSSION: Imatinib mesylate is a protein tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the receptor tyrosine kinases for platelet-derived growth factor, and stem cell factor c-kit. Prostate cancer has been identified as a target for therapy with imatinib mesylate. This patient had no other confounding factors for the cause of the renal failure. An objective causality assessment determined that imatinib mesylate was the probable cause of the acute renal failure. The presence of a primary glomerular disease was excluded by biopsy.

CONCLUSIONS: Imatinib mesylate-induced acute renal failure has now been linked to toxic effects on renal tubular cells in 3 cases. Renal function should be closely monitored during imatinib mesylate therapy.

Key Words: acute renal failure, imatinib mesylate

Published Online, November 15, 2005. www.theannals.com, DOI 10.1345/aph.1G131

This article has been cited by other articles:

				S. K. Winn, S. Ellis, P. Savage, S. Sampson, and J. E. Marsh Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol. Dial. Transplant., February 1, 2009; 24(2): 673 - 675. [Abstract] [Full Text] [PDF]

				E. V. Verona, Y. Tang, T. K. Millstead, A. P. Hinck, J. K. Agyin, and L.-Z. Sun Expression, purification and characterization of BGERII: a novel pan-TGF{beta} inhibitor Protein Eng. Des. Sel., July 1, 2008; 21(7): 463 - 473. [Abstract] [Full Text] [PDF]